Pathologic features the urologist should expect on a prostate biopsy

Urologic Oncology: Seminars and Original Investigations

Volumn 21, Issue 2, 2003, Pages 153-161

  Che, Mingxin ^a   Sakr, Wael ^a   Grignon, David ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Atypical small acinar proliferation; High grade prostatic intraepithelial neoplasia; Minimal cancer; Prostate biopsy; Repeat biopsy

Indexed keywords

ACINAR CELL; CANCER DIAGNOSIS; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURGERY; CELL PROLIFERATION; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; NEEDLE BIOPSY; PATIENT COUNSELING; PERINEURIUM; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME; TUMOR BIOPSY; CANCER STAGING; MALE; PATHOLOGY; PREDICTION AND FORECASTING; PROSTATE; PROSTATE TUMOR; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; UROLOGY;

BIOPSY, NEEDLE; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; UROLOGY;

EID: 0042386272     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(03)00008-5     Document Type: Conference Paper

References (77)

1. Randolph TL, Amin MB, Ro JY, Ayala, AG. Histologic variants of adenocarcinoma and other carcinomas of prostate: pathologic criteria and clinical significance. Mod Pathol 1997;10:612-29.
2. Grignon DJ, Hammond EH. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Prostate Cancer Working Group. Arch Pathol Lab Med 1995;119:1122-6.
3. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, Chisholm GD, Moskovitz B, Livne PM, Warner J. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330:242-8.
4. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993;71:3582-93.
5. Zagars GK, Pollack A, von Eschenbach AC. Prognostic factors forclinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Cancer 1997;79:1370-80.
6. Roach M, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry R, Grignon D, Mohuidden M. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 2000;47:609-15.
7. Roach M 3rd, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry R, Grignon D. Long-term survival after radiotherapy alone: radiation therapy oncology group prostate cancer trials. J Urol 1999;161:864-8.
8. Pilepich MV, Krall JM, al-Sarraf M, John MJ, Doggett RL, Sause WT, Lawton CA, Abrams RA, Rotman M, Rubin P, et al. Androgen deprivation withradiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995;45:616-23.
9. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-52.
10. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep 1966;50:125-8.
11. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988;12:897-906.
12. Lee F, Siders DB, Torp-Pedersen ST, Kirscht JL, McHugh TA, Mitchell AE. Prostate cancer: transrectal ultrasound and pathology comparison. A preliminary study of outer gland (peripheral and central zones) and inner gland (transition zone) cancer. Cancer 1991;67:1132-42.
13. Epstein JI, Pound CR, Partin AW, Walsh PC. Disease progression following radical prostatectomy in men with Gleason score 7 tumor. J Urol 1998;160:97-100 discussion 101.
14. Tefilli MV, Gheiler EL, Tiguert R, Banerjee M, Sakr W, Grignon DJ, Pontes JE, Wood DP, Jr. Prognostic indicators in patients with seminal vesicle involvement following radical prostatectomy for clinically localized prostate cancer. J Urol 1998;160:802-6.
15. Tefilli MV, Gheiler EL, Tiguert R, Sakr W, Grignon DJ, Banerjee M, Pontes JE, Wood DP, Jr. Should Gleason score 7 prostate cancer be considered a unique grade category? Urology 1999;53:372-7.
16. Makarov DV, Sanderson H, Partin AW, Epstein JI. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 3 and 3 4 independent of the number of involved cores? J Urol 2002;167:2440-2442.
17. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001;28:555-65.
18. Sakr WA, Tefilli MV, Grignon DJ, Banerjee M, Dey J, Gheiler EL, Tiguert R, Powell IJ, Wood DP. Gleason score 7 prostate cancer: a heterogeneous entity? Correlation with pathologic parameters and disease-free survival. Urology 2000;56:730-4.
19. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001;58:843-8.
20. Moul JW. Prostate biopsy quantitative histology as a staging and prognostic factor. J Urol 2002;167:526-7.
21. Freedland SJ, Csathy GS, Dorey F, Aronson WJ. Percent prostate needle biopsytissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J Urol 2002;167:516-20.
22. Grossklaus DJ, Coffey CS, Shappell SB, Jack GS, Chang SS, Cookson MS. Percent of cancer in the biopsy set predicts pathological findings after prostatectomy. J Urol 2002;167:2032-5 discussion 2036.
23. Freedland SJ, Csathy GS, Dorey F, Aronson WJ. Clinical utility of percent prostate needle biopsy tissue with cancer cutpoints to risk stratify patients before radical prostatectomy. Urology 2002;60:84-8.
24. Grossfeld GD, Latini DM, Lubeck DP, Broering JM, Li YP, Mehta SS, Carroll PR. Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE. Urology 2002;59:560-5.
25. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Fondurulia J, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 2000;18:1164-72.
26. Nelson CP, Rubin MA, Strawderman M, Montie JE, Sanda MG. Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy. Urology 2002;59:740-5.
27. Conrad S, Graefen M, Pichlmeier U, Henke RP, Erbersdobler A, Hammerer PG, Huland H. Prospective validation of an algorithm with systematic sextant biopsy to predict pelvic lymph node metastasis in patients with clinically localized prostatic carcinoma. J Urol 2002;167:521-5.
28. Sebo TJ, Cheville JC, Riehle DL, Lohse CM, Pankratz VS, Myers RP, Blute ML, Zincke H. Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer. Am J Surg Pathol 2002;26:431-9.
29. Bonin SR, Hanlon AL, Lee WR, Movsas B, al-Saleem TI, Hanks GE. Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy. Cancer 1997;79:75-80.
30. O'Malley KJ, Pound CR, Walsh PC, Epstein JI, Partin AW. Influence of biopsy perineuralinvasion on long-term biochemical disease-free survival after radical prostatectomy. Urology 2002;59:85-90.
31. Allepuz Losa CA, Sanz Velez JI, Gil Sanz MJ, Mas LP, Rioja Sanz LA. Seminal vesicle biopsy in prostate cancer staging. J Urol 1995;154:1407-11.
32. Stock RG, Stone NN, Ianuzzi C, Unger P. Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: implications for patient selection in the radiotherapeutic management of prostate cancer. Int J Radiat Oncol Biol Phys 1995;33:815-21.
33. Stone NN, Stock RG, Unger P. Indications for seminal vesicle biopsy and laparoscopic pelvic lymph node dissection in men with localized carcinoma of the prostate. J Urol 1995;154:1392-6.
34. Rubin MA, Dunn R, Kambham N, Misick CP, O'Toole KM. Should a Gleason score be assigned to a minute focus of carcinoma on prostate biopsy? Am J Surg Pathol 2000;24:1634-40.
35. O'Malley FP, Grignon DJ, Shum DT. Usefulness of immunoperoxidase staining with high-molecular-weight cytokeratin in the differential diagnosis of small-acinar lesions of the prostate gland. Virchows Arch A Pathol Anat Histopathol 1990;417:191-6.
36. Wojno KJ, Epstein JI. The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases. Am J Surg Pathol 1995;19:251-60.
37. Shah RB, Zhou M, LeBlanc M, Snyder M, Rubin MA. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol 2002;26:1161-8.
38. Parsons JK, Gage WR, Nelson WG, De Marzo AM. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology 2001;58:619-24.
39. Signoretti S, Waltregny D, Dilks J, Issac B, Lin D, Garraway L, Yang A, Montironi R, McKeon F, Loda M. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000;157:1769-75.
40. Fernandes ET, Sundaram CP, Long R, Soltani M, Ercole CJ. Biopsy Gleason score: how does it correlate with the final pathological diagnosis in prostate cancer? Br J Urol 1997;79:615-7.
41. Narain V, Bianco FJ Jr, Grignon DJ, Sakr WA, Pontes JE, Wood DP, Jr. How accurately does prostate biopsy Gleason score predict pathologic findings and disease free survival? Prostate 2001;49:185-90.
42. Steinberg DM, Sauvageot J, Piantadosi S, Epstein JI. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 1997;21:566-76.
43. Sakr WA, Grignon DJ. Prostate. Practice parameters, pathologic staging, and handling radical prostatectomy specimens. Urol Clin North Am 1999;26:453-63v.
44. Fukagai T, Namiki T, Namiki H, Carlile RG, Shimada M, Yoshida H. Discrepancies between Gleason scores of needle biopsy and radical prostatectomy specimens. Pathol Int 2001;51:364-70.
45. Mills SE, Fowler JE. Gleason histologic grading of prostatic carcinoma. Correlations between biopsy and prostatectomy specimens. Cancer 1986;57:346-9.
46. Yang XJ, Lecksell K, Potter SR, Epstein JI. Significance of small foci of Gleason score 7 or greater prostate cancer on needle biopsy. Urology 1999;54:528-32.
47. Thorson P, Vollmer RT, Arcangeli C, Keetch DW, Humphrey PA. Minimal carcinoma in prostate needle biopsy specimens: diagnostic features and radical prostatectomy follow- up. Mod Pathol 1998;11:543-51.
48. Rabbani F, Stroumbakis N, Kava BR, Cookson MS, Fair WR. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol 1998;159:1247-50.
49. Djavan B, Ravery V, Zlotta A, Dobronski P, Dobrovits M, Fakhari M, Seitz C, Susani M, Borkowski A, Baccon-Gibod L, Schulman CC, Marberger M. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 2001;166:1679-83.
50. Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol 2002;167:2435-9.
51. Bostwick DG, Qian J, Frankel K. The incidence of high grade prostatic intraepithelial neoplasia in needle biopsies. J Urol 1995;154:1791-4.
52. Hoedemaeker RF, Kranse R, Rietbergen JB, Kruger AE, Schroder FH, van der Kwast TH. Evaluation of prostate needle biopsies in a population-based screening study: the impact of borderline lesions. Cancer 1999;85:145-52.
53. Hu JC, Palapattu GS, Kattan MW, Scardino PT, Wheeler TM. The association of selected pathological features with prostate cancer in a single-needle biopsy accession. Hum Pathol 1998;29:1536-8.
54. Langer JE, Rovner ES, Coleman BG, Yin D, Arger PH, Malkowicz SB, Nisenbaum HL, Rowling SE, Tomaszewski JE, Wein AJ, Jacobs JE. Strategy for repeat biopsy of patients with prostatic intraepithelial neoplasia detected by prostate needlebiopsy. J Urol 1996;155:228-31.
55. Mettlin C, Lee F, Drago J, Murphy GP. The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer 1991;67:2949-58.
56. Orozco R, O'Dowd G, Kunnel B, Miller MC, Veltri RW. Observations on pathology trends in 62,537 prostate biopsies obtained from urology private practices in the United States. Urology 1998;51:186-95.
57. Renshaw AA, Santis WF, Richie JP. Clinicopathological characteristics of prostatic adenocarcinoma in men with atypical prostate needle biopsies. J Urol 1998;159:2018-21 discussion 2022.
58. Wills ML, Hamper UM, Partin AW, Epstein JI. Incidence of high-grade prostatic intraepithelial neoplasia in sextant needle biopsy specimens. Urology 1997;49:367-73.
59. Keetch DW, Humphrey P, Stahl D, Smith DS, Catalona WJ. Morphometric analysis and clinical followup of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate. J Urol 1995;154:347-51.
60. O'Dowd GJ, Miller MC, Orozco R, Veltri RW. Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. Urology 2000;55:553-9.
61. Borboroglu PG, Sur RL, Roberts JL, Amling CL. Repeat biopsy strategy in patients with atypical small acinar proliferation or high grade prostatic intraepithelial neoplasia on initial prostate needle biopsy. J Urol 2001;166:866-70.
62. Park S, Shinohara K, Grossfeld GD, Carroll PR. Prostate cancer detection in men with prior high grade prostatic intraepithelial neoplasia or atypical prostate biopsy. J Urol 2001;165:1409-14.
63. Kronz JD, Allan CH, Shaikh AA, Epstein JI. Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy. Am J Surg Pathol 2001;25:1079-85.
64. Bostwick DG, Amin MB, Dundore P, Marsh W, Schultz DS. Architectural patterns of high- grade prostatic intraepithelial neoplasia. Hum Pathol 1993;24:298-310.
65. Bostwick DG, Srigley J, Grignon D, Maksem J, Humphrey P, van der Kwast TH, Bose D, Harrison J, Young RH. Atypical adenomatous hyperplasia of the prostate: morphologic criteria for its distinction from well- differentiated carcinoma. Hum Pathol 1993;24:819-32.
66. Iczkowski KA, Chen HM, Yang XJ, Beach RA. Prostate cancer diagnosed after initial biopsy with atypical small acinar proliferation suspicious for malignancy is similar to cancer found on initial biopsy. Urology 2002;60:851-4.
67. Cheville JC, Reznicek MJ, Bostwick DG. The focus of "atypical glands suspicious for malignancy" in prostatic needle biopsy specimens: incidence, histologic features, and clinical follow-up of cases diagnosed in a community practice. Am J Clin Pathol 1997;108:633-40.
68. Iczkowski KA, Bassler TJ, Schwob VS, Bassler IC, Kunnel BS, Orozco RE, Bostwick DG. Diagnosis of "suspicious for malignancy" in prostate biopsies: predictive value for cancer. Urology 1998;51:749-57discussion 757-8.
69. Chan TY, Epstein JI. Follow-up of atypical prostate needle biopsies suspicious for cancer. Urology 1999;53:351-5.
70. Alsikafi NF, Brendler CB, Gerber GS, Yang XJ. High-grade prostatic intraepithelial neoplasia with adjacent atypia is associated with a higher incidence of cancer on subsequent needle biopsy than high-grade prostatic intraepithelial neoplasia alone. Urology 2001;57:296-300.
71. Kronz JD, Shaikh AA, Epstein JI. High-grade prostatic intraepithelial neoplasia with adjacent small atypical glands on prostate biopsy. Hum Pathol 2001;32:389-95.
72. Kamoi K, Troncoso P, Babaian RJ. Strategy for repeat biopsy in patients with high grade prostatic intraepithelial neoplasia. J Urol 2000;163:819-23.
73. Allen EA, Kahane H, Epstein JI. Repeat biopsy strategies for men with atypical diagnoses on initial prostate needle biopsy. Urology 1998;52:803-7.
74. Lefkowitz GK, Sidhu GS, Torre P, Lepor H, Taneja SS. Is repeat prostate biopsy for high-grade prostatic intraepithelial neoplasia necessary after routine 12-core sampling? Urology 2001;58:999-1003.
75. Lefkowitz GK, Taneja SS, Brown J, Melamed J, Lepor H. Followup interval prostatebiopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels. J Urol 2002;168:1415-8.
76. Mian BM, Naya Y, Okihara K, Vakar-Lopez F, Troncoso P, Babaian RJ. Predictors of cancer in repeat extended multisite prostate biopsy in men with previous negative extended multisite biopsy. Urology 2002;60:836-40.
77. Kestin LL, Goldstein NS, Vicini FA, Martinez AA. Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy. J Urol 2002;168:1994-9.